Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to Castle Biosciences Fourth Quarter and Full Year 2023 Conference Call. As a reminder, today's call is being recorded.
Stay updated with breaking news from Tissuecypher Barrett. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Operator: Good afternoon, and welcome to Castle Biosciences Fourth Quarter and Full Year 2023 Conference Call. As a reminder, today's call is being recorded.
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Nov 2, 2023--
Q3 2023 revenue increased 66% over Q3 2022 to $61 million Q3 2023 total test reports increased 52% over Q3 2022 Raising full year 2023 revenue guidance to at least $200 million from at least $180...
The study, published in Gastroenterology, shows TissueCypher can increase the detection of Barrett’s esophagus patients with an initial diagnosis of low-grade dysplasia who will progress to...
In the study, management decisions were simulated to determine the most likely care plan with or without use of the TissueCypher test for guidance Study data shows TissueCypher test results...